T-cell Malignancies
📧 Sign up to get email alerts when something new happens for T-cell Malignancies.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) [Phase 1]
Electra Therapeutics is conducting a Phase 1 trial of ELA026 in relapsed/refractory T-cell and NK/T-cell malignancies, and the study is curr…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies [Phase 1, Phase 2]
A multicenter Phase 1/2 open-label, single-arm study evaluating nanobody-based CD5-CAR T cell therapy for relapsed/refractory T-cell maligna…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating autologous and donor-derived CD7 CAR-T cell therapy for refractory or relapsed T-cell malignancies,…
-
CLINICAL_TRIALS trial_result · 2025-06-12Clinical Trial Update: Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies [Phase 1]
Phase 1 trial evaluating a combination of romidepsin, CC-486 (oral azacitidine), dexamethasone, and lenalidomide (RAdR) for relapsed/refract…